Alliance A021501 Trial Establishes FOLFIRINOX as Preferred Treatment Regimen
In a study of patients with borderline resectable pancreatic cancer, combination chemotherapy with modified FOLFIRINOX before surgery increased survival relative to historical data and compared favorably to FOLFIRINOX plus hypofractionated radiotherapy, according to research from The University of Texas MD Anderson Cancer Center published today in JAMA Oncology.
The multicenter, randomized phase II Alliance A021501 clinical trial, part of the National Cancer Institute’s National Clinical Trials Network, established presurgical, or neoadjuvant, FOLFIRINOX as the preferred therapy for these patients. Early results from this study were first presented at the American Society of Clinical Oncology 2021 Gastrointestinal Cancers Symposium. Read more.
Related Posts
Lung-MAP Shows Potential of Public-Private Partnerships
Ten years on, Lung-MAP success demonstrates potential of public-private partnerships in clinical research
Bladder Cancer Subtype Association with Response
RNA-based molecular subtypes modestly improved predictions for pathologic downstaging in muscle-invasive bladder cancer.
Lung-MAP Broadens Trial Access for Some Groups
As compared to conventional, stand-alone clinical trials in advanced non-small cell lung cancer, the biomarker-driven Lung-MAP trial has enrolled higher percentages of patients who are older, patients who are from rural or socioeconomically deprived areas, and patients who have Medicaid or no insurance